On December 29, 2023, OrthoPediatrics Corp. (the ?Company?) entered into a $80 million Credit, Security and Guaranty Agreement (the ?Credit Agreement?) by and among (i) the Company and other borrowers party to the Credit Agreement (collectively, the ?Borrowers?), (ii) MidCap Funding IV Trust, as Agent (?Agent?), (iii) MidCap Financial Trust, as Term Loan Servicer (?Servicer?), and (iv) the financial institutions or other entities from time to time party thereto as Lenders (collectively, ?Lenders?). Under the terms of the Credit Agreement, the Lenders have provided to Borrowers a term loan in an aggregate principal amount that will not exceed $30 million available in three tranches of $10 million each subject to certain conditions (the ?Term Loan?) and a revolving loan in an aggregate principal amount that will not exceed $50 million (the ?Revolving Loan?).

Interest on the Term Loan will accrue at the greater of (a) One Month Term SOFR plus 6.50% or (b) 9.0% and interest on the Revolving Loan will accrue at the greater of (a) One Month Term SOFR plus 4.0% or (b) 6.50% (the ?Applicable Rate?) and will be payable monthly by the Borrowers. The first tranche of $10 million was issued under the Term Loan upon execution. Payments of principal and all accrued but unpaid interest will be due and payable upon the earlier of December 1, 2028, or (i) the occurrence of any transaction or series of transactions pursuant to which any person or entity in the aggregate acquire(s) 35% or more of the voting capital stock of the Company (ii) a change in the majority of the Company?s Board of Directors over a 12-month period; (iii) the Company ceases to own directly or indirectly, 100% of the capital stock of any of its subsidiaries (with the exception of any subsidiaries permitted to be dissolved, merged or otherwise disposed of by the Credit Agreement), or (iv) the occurrence of a change in control, fundamental change, deemed liquidation event or terms of similar import under any document or instrument governing or relating to debt of or equity interests of Company.

The loans under the Credit Agreement are secured by a security interest in the Company?s and other Borrower?s assets. The Credit Agreement provides for customary events of default. If an event of default is not cured within the time periods specified (if any), the Lenders and Agent have the right to accelerate the Company?s payment of principal and interest in addition to other rights and remedies.

The debt facilities available under the Credit Agreement replace the Fourth Amended and Restated Loan and Security Agreement with Squadron Capital LLC (?Squadron?) (as amended, the ?Squadron Loan Agreement?), which provided the Company with a $50 million revolving credit facility. There was no indebtedness outstanding under the Squadron Loan Agreement and it was terminated in connection with the Credit Agreement.